FDA Says Popular , Nasal Decongestant , Not Effective Treatment For Congestion.
Associated Press reports that government experts found that the number one decongestant in the United States does not alleviate a stuffy nose.
.
Associated Press reports that government experts found that the number one decongestant in the United States does not alleviate a stuffy nose.
.
On September 12, advisers for the Food and Drug Administration voted unanimously against the effectiveness of phenylephrine.
Phenylephrine is found in a number of popular over-the-counter products, including Sudafed, Allegra and Dayquil.
Modern studies, when well conducted, are not showing any improvement in congestion with phenylephrine, Dr. Mark Dykewicz, Allergy specialist at the Saint Louis University School of Medicine, via Associated Press.
AP reports that a team of outside advisers were assembled by the FDA to take a closer look at the effectiveness of phenylephrine.
Phenylephrine became the key ingredient in decongestants in 2006, when pseudoephedrine was ordered to be moved behind pharmacy counters.
Phenylephrine became the key ingredient in decongestants in 2006, when pseudoephedrine was ordered to be moved behind pharmacy counters.
The change came after a 2006 law called for the change, as pseudoephedrine can be used to produce methamphetamine.
.
The change came after a 2006 law called for the change, as pseudoephedrine can be used to produce methamphetamine.
.
AP reports that pending the FDA's decision, drugmakers like Johnson & Johnson and Bayer could be ordered to pull oral medications with phenylephrine.
.
AP reports that pending the FDA's decision, drugmakers like Johnson & Johnson and Bayer could be ordered to pull oral medications with phenylephrine.
.
According to the FDA's panel of experts, consumers would need to be educated on remaining options for treating congestion.
Patients require and deserve medications that treat their symptoms safely and effectively and I don’t believe that this medication does that, Jennifer Schwartzott, the patient representative on the FDA panel, via Associated Press
